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ABSTRACT 
Highly pathogenic avian influenza (HPAI) H5N1 viruses are a class of emerging zoonotic 
viruses that present a significant threat to global health.  Seasonal influenza causes an estimated 
3-5 million illnesses a year, presenting a significant public health burden.  Surveillance and 
research into the clinical and immunological mechanisms of emerging avian influenza viruses 
like H5N1 with pandemic potential is important to safeguarding public health worldwide.  H5N1 
strains are endemic in wild and domestic birds worldwide, but very rarely infect humans.  When 
spillover into humans does occur, however, H5N1 causes severe disease, acute respiratory 
distress, and has a high case fatality rate.  The high pathogenic potential of this virus makes a 
compelling argument for understanding the underlying pathological and immunological 
mechanisms of the disease.  Our lab has demonstrated in a nonhuman primate model that 
aerosolized infection with H5N1 influenza virus leads to disease progression similar to that seen 
in human cases.  This study aims to characterize some of the innate immune cells that contribute 
to the response to severe H5N1 infection in this macaque model.  Natural killer (NK) cells are a 
critical cytotoxic innate responder to viral infection, and innate lymphoid cells (ILCs) are a 
recently discovered subset of the innate immune system that are thought to have a critical impact 
on early response to viral infection in the lung.  These cells were characterized and quantified in 
lung tissue of both naïve and H5N1 infected cynomolgous macaques.  I found that NK cells 
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showed a significant decrease in frequency in infected animals, perhaps indicating infection and 
subsequent loss relative to naïve animals.  I was also able to identify two populations of CD45+ 
cells lacking lineage markers (CD3/CD20/CD163) in the macaque lung that are analogous to 
previously defined type 2 ILCs expressing CRTH2 but do not express CD127, and a population 
of type 3 ILCs that co-expressed CD127 and CD117.  CRTH2+ cells accumulated non-
significantly in the lungs of H5N1 infected animals in response to influenza virus, suggesting 
that they are stimulated and recruited by infection, and likely have a protective immune response.  
Further characterization of ILC and NK cell subsets in the lung and their functional response to 
severe acute respiratory infection such as H5N1 provides a promising avenue for understanding 
the early innate response to influenza infection. 
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1.0  INTRODUCTION 
Influenza virus is a small, enveloped RNA virus belonging to the family Orthomyxoviridae 
that can be found in many different species.  Phylogenetically, influenza viruses originate 
from wild waterfowl as their natural host, but have evolved to routinely infect domestic 
poultry and a wide variety of mammals1.  Avian influenzas circulate worldwide in both wild 
and domestic birds.  Human seasonal influenza strains are endemic in the population, causing 
between 3 to 5 million infections a year and resulting in approximately 250,000-500,000 
deaths worldwide2.  Influenza viruses are divided into three subtypes (A, B and C), of which 
influenza A viruses are primarily responsible for the burden of human disease.  Influenza 
virus mutates rapidly, which results in a wide variety of strains whose epidemiology shifts 
from year to year.  The virus has two main surface glycoproteins, hemagglutinin (HA) and 
neuraminidase (NA), which are used to subtype the virus based on reactivity to human 
antibodies.  Influenza A subtypes are named after their species of origin (if other than 
human), site of isolation, number of isolate, year of isolation, and then by HA and NA 
subtype  (e.g. A/goose/Guangdong/1/96 H5N1)3.  Currently, the circulating human strains of 
influenza A are of the H1N1 and H3N2 subtypes2.   
In humans, influenza virus infection is transmitted by inhalation of airborne particles, 
droplets, and contact with contaminated surfaces via fomites.  Infection causes acute 
respiratory disease, as well as symptoms such as fever and general malaise, although 
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complications such as secondary pneumonia can arise4.  The case fatality rate of seasonal 
influenza disease is relatively low, although there are several populations who are at higher 
risk of mortality and complications due to influenza virus infection, including people over the 
age of 65, children under the age of 5, and pregnant women2.  While mortality is typically 
low, due to its widespread prevalence in the human population and ability to mutate into new 
strains, influenza virus is widely considered to be one of the greatest threats for a human 
pandemic disease.  Pandemics occur when a new strain is introduced to the human 
population, typically through a species crossover event, and spreads rapidly.  In 1918 for 
example, a strain of H1N1 influenza virus known as the Spanish Flu caused the worst 
recorded influenza pandemic in human history that is estimated to have killed 50 million 
people worldwide.  Influenza pandemics of some degree occur about every 40 years5.  As 
such, influenza monitoring and surveillance is an ongoing public health priority. 
1.1 INFLUENZA BIOLOGY AND EPIDEMIOLOGY 
The influenza viral genome is single stranded, negative sense RNA that is divided into eight 
segments which encode a total of 10 proteins: 3 RNA polymerase components (PB1, PB2 and 
PA), the viral nucleoprotein, two matrix proteins (M1 and M2), two nonstructural proteins (NS1 
and NS2), and the surface glycoproteins HA and NA3. 
3 
Figure 1. Influenza Virion 
Schematic representation of influenza virion and structural proteins.  Source: Szewczyk et al.3 
The surface proteins, HA and NA play an integral role in virus entry and release, respectively. 
HA binds sialic acid-galactose receptors on the surface of host cells to facilitate entry.  
Variations in HA protein structure contribute to the species-specificity of virus, by preferentially 
binding different forms of glycosidic linkages.  In human influenza viruses, the preference is for 
sialic acids covalently attached to galactose via an α2,6.  Avian strains of the virus, however, 
primarily use α2,3 linkages to infect cells which line the intestinal tract of many species of 
waterfowl and domestic poultry.  This explains the fact that strains have evolved some degree of 
species-specificity, but it is important to note that the binding of these linkages is preferential, 
not absolute3.  Point mutations in the HA protein or infection with high inoculum doses of the 
virus can be enough to overcome this preference to cause cross-species infection.  The NA 
protein is responsible for cleaving sialic acid from the surface of infected cells, facilitating viral 
release by preventing recapture of virions through HA re-binding to host cells. 
Rapid evolution is a key aspect of influenza epidemiology, which is driven by two 
factors, an error-prone RNA polymerase, and the segmentation of the influenza genome.  The 
RNA polymerase used to copy the influenza genome during viral replication possesses no error-
checking activity, and as such is highly likely to introduce point mutations during genomic 
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replication.  The accumulation of these mutations over time leads to what is referred to as 
antigenic drift, as gradual changes to the genome result in new viral variants that are not 
neutralized by the immune system.  This applies to the surface proteins HA and NA in particular, 
as they are the primary target of neutralizing antibody activity and immunological memory, 
hence why influenza strains are classified according to antibody cross-reactivity of these 
proteins.  Strain variants resulting from antigenic drift often contain some degree of overlap, and 
the immune system is able to at least partially recognize similar strains from year to year, 
resulting in varying degrees of immunity throughout the population to seasonal strains. 
 Pandemic strains, on the other hand, often arise from what is termed antigenic shift.  
Antigenic shift is the reassortment of genome segments between two different influenza viruses 
when more than one virus strain infects the same cell in a host.  This can lead to rapid jumps in 
evolution that create entirely new genetic variants to which the host has no prior immunity, and 
these can transmit rapidly through a susceptible population.  Cross-species antigenic shifts 
commonly take place in an intermediary host that can be infected with multiple strains from 
different species.  Domestic swine are commonly considered to be a mixing vessel for 
reassortment between human and avian strains of influenza.  The resulting virus is considered to 
have pandemic potential if it is easily transmissible from person-to-person.  Furthermore, viruses 
that undergo antigenic shift and make a zoonotic jump between species could undergo further 
antigenic drift mutations of their HA protein to select for preferential binding of the new host’s 
sialic acid receptors, resulting in a new HA variant subtype that is newly species-specific for that 
host. 
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1.1.1 H5N1 High Pathogenicity Avian Influenza 
As previously mentioned, the natural host of avian influenza viruses are wild waterfowl, and 
transmission among wild birds is common.  Often infection within these species is 
asymptomatic.  Influenza viruses also can circulate between wild birds and domestic poultry.  
Avian influenza typically refers to a group of viruses which normally infects only birds, and 
there are several different avian influenzas currently circulating throughout the world, including 
H5N1, H5N8, H5N6, H7N9 and H9N2 subtypes6.  In birds, there are two classifications of avian 
influenza, low or high pathogenicity.  Low pathogenicity avian influenza (LPAI) only causes 
mild symptoms, whereas high pathogenicity avian influenza (HPAI) is characterized by severe 
systemic disease and fatality rates sometimes nearing 100% in domestic poultry6.  The 
pathogenicity of the strain can vary greatly between species, however, strains that cause disease 
in domestic poultry are of particular concern both due to their potential economic impact as well 
as the proximity to humans and potential for zoonotic transmission.  There have been several 
instances of avian influenza viruses infecting humans, usually with cases of human-to-human 
transmission limited to close primary contacts such as immediate family and caregivers, but 
these spillover events tend to cause high morbidity and mortality4.  H5 viruses in particular have 
been a cause for concern because there have been multiple cases of human H5 infection the past 
several decades6. 
 The first known case of H5 influenza transmission to humans occurred in Hong Kong in 
1997, as a result of the A/goose/Guangdong/1/96 virus.  Viruses belonging to this lineage have 
since spread throughout the world and mutated to form a diverse repertoire of strains.  Since 
1997, human cases of H5 viruses have been reported in more than 60 countries6.  There have 
been 856 human cases reported as of January 2017 across five continents, with a case fatality 
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rate exceeding 50%6.  Human infection with H5N1 results in severe disease that is characterized 
by rapid onset of acute respiratory distress syndrome (ARDS), high viral load, and intense 
inflammation, which leads to rapid death7.  Despite the severity of disease seen in humans, there 
have been no recorded instances of sustained human-to-human transmission.  However, as H5N1 
viruses continue to circulate in bird populations throughout the world, it continues to be 
monitored as a potential pandemic threat, and monitored for potential mutations that could 
facilitate human-to-human transmission. 
1.1.2 Host response to influenza infection 
The host response to influenza virus comprises of both innate and adaptive immune responses.  
After infection through aerosolized droplets or contact with fomites, infection initiates in the 
respiratory tract where the virus can infect both immune and non-immune cells.  Recognition of 
the virus by innate immune sensing mechanisms stimulates the production of type 1 interferons 
(IFNs) which lead to induction of an antiviral state.  The production of pro-inflammatory 
cytokines leads to many of the generalized symptoms of influenza, such as fever, and malaise, 
but also serves to begin the recruitment of innate cell types, including neutrophils, monocytes 
and natural killer cells.8  Adaptive immune responses to influenza infection are quite complex, 
and have been reviewed many times in the context of immune response to vaccination9.  Briefly, 
influenza is able to induce both an antibody response, largely against the two main surface 
glycoproteins, HA and NA, as well as a robust CD8+ and CD4+ T cell response.  This leads to 
the generation of immunological memory, but the rapid mutation of the virus means that the 
strain-specificity of the adaptive immunity does not protect against new and emergent strains 
after a single infection.9  Another important feature of the host response to influenza is the 
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potential for immunopathology caused by intense immune responses.  Due to widespread viral 
replication, recruitment and activation of immune cells occurs rapidly.  While viral mediated cell 
death and tissue damage causes much of the pathology of influenza, there is evidence of CD8+ T 
cell mediated tissue damage as well, and excess production of cytokines causes exacerbation of 
inflammation in severe disease10. 
 In this study, we specifically focus on the innate response to influenza virus as mediated 
by innate lymphoid cell subsets.   
 
1.2 INNATE LYMPHOID CELLS 
ILCs are a broad, heterogeneous population of cells that are responsible for several crucial 
functions of the early innate immune response, including promoting homeostasis, tissue repair, 
and regulation of inflammation11-13.  They are distributed throughout the body in various 
lymphoid and non-lymphoid tissues, but have been shown to be enriched at mucosal surfaces13.  
All ILCs develop from a single common lymphoid progenitor12, which then differentiates into a 
common natural killer (NK) cell progenitor and a common helper ILC progenitor.  The common 
helper ILC progenitor further differentiates into three subtypes14 (ILC1, 2 and 3) of non-lytic 
ILCs that are defined based on their required transcription factors and cytokine expression.   
There is limited universal nomenclature and definition of various subtypes of ILCs, and 
some research suggests that expression of surface markers can vary depending on the tissue of 
residence and cytokine environment, as well as the fact that there is some level of plasticity 
between the ILC types13, 14.  All the non-cytotoxic ILCs react indirectly to pathogens by sensing 
 8 
cytokines derived from myeloid or epithelial cells.  In turn, they are believed to drive and 
amplify both innate and adaptive immune responses by producing cytokines associated with 
particular T cell types and feedback loops13.  This makes them potent activators of the immune 
response, and they play a critical role in the regulation of immunity and inflammation. 
1.2.1 Type 1 ILCs and classical NK cells 
ILC1s include classical natural killer (NK) cells, as well as non-cytotoxic ILC1s.  All ILC1s 
including NK cells express the transcription factor Tbet, while non-toxic ILC1s express both 
Tbet and Eomes12.   Classical NK cells express the functional proteins perforin and granzyme b, 
and non-toxic ILC1s produce IFN-γ in response to interleukin (IL)-1215.  There are also several 
emerging subsets of ILC1 that are as of yet poorly characterized16.  
While NK cells are traditionally classified in with ILC1s due to their expression of the 
characteristic transcription factor Tbet, they are distinct from other ILC subtypes in several ways.  
For one, NK cells are effector cells, involved in direct recognition and killing of infected host 
cells, as opposed to the rest of the ILCs which take on a non-cytotoxic helper role by producing 
cytokines that marshal the immune response11.  Additionally, NK cells differentiate from the 
common innate lymphoid progenitor cell earlier in their development than the rest of the non-
cytotoxic ILC subtypes14.  NK cells are the body’s first line of defense in response to 
intracellular pathogens.   They are primarily located in secondary lymphoid tissues, and are 
recruited to the site of infection via chemokine signaling, again in contrast to other ILCs, which 
are tissue-resident13.  They play a pivotal role in the innate response against viruses, and have 
been implicated in control of both acute and chronic viral infection17.  NK cells express several 
 9 
activating receptors, NKp46, NKp44 and NKp30 (alternatively referred to as NCR1, NCR2 and 
NCR3), as well as the NKG2 family of activating and inhibitory receptors18.   
While NK cell activity has been shown to play a critical role in influenza immunity, there 
are also several demonstrated mechanisms of evasion of NK cell defenses18.  The NK cell natural 
cytotoxicity receptor NKp46 contains sialic acid residues, and as such are able to recognize the 
viral HA protein19.  This interaction makes influenza virus a ready target for NK cell-mediated 
viral clearance, but also means that NK cells are susceptible to infection.  Additionally, it is 
hypothesized that rapid mutation of HA among influenza strains contributes to influenza’s 
effective evasion of NK cell defenses.  Additionally, it has been shown that both seasonal and 
avian influenza strains can directly infect NK cells18, 20 and have been shown to induce NK cell 
death as well as inhibition of activation20.  Therefore, studying NK cell responses in an in vivo 
model could provide insights into their reaction to fatal influenza infection. 
1.2.2 Type 2 ILCs  
Type 2 ILCs are characterized by the expression of IL-13 and IL-5 in response to stimulation by 
IL-33 and IL-25, a cytokine expression profile that is analogous to type 2 helper T cells (Th2)12, 
21-23.  They rely on the transcription factor GATA-3 for their development, and express several 
characteristic surface markers including IL7-Rα, CD25, Sca-1, ST2, CD161 and CRTH212, 21, 23 
in mice and humans.  CRTH2 is a marker that is associated with Th2 immune responses23 that 
prevents apoptosis and mediates chemotaxis to sites of allergic inflammation.   
 The cytokines produced by ILC2s, especially IL-13 have been shown to induce allergic 
inflammation, and ILC2s have been studied in various allergic diseases, asthma and also 
response to helminth infection14.  Various innate immune cell subtypes produce IL-33 as a 
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danger signal and activate a feedback loop12 that results in the recruitment of ILC2s.  ILC2s also 
produce IL-5 which induces eosinophils and related effector responses, further resulting in the 
priming of  Th2 response through recruitment or facilitating antigen presentation12.  ILC2s have 
been extensively studied in the lung as a mediator of airway inflammation and cellular repair 
mechanisms, which is particularly important in the context of influenza infection.   
1.2.3 Type 3 ILCs 
Type 3 ILCs produce IL-22 and IL-17 in response to IL-2312, 23, which is analogous to the 
functional profile of Th17 cells.  They rely on the transcription factor RORγ for their 
development and function12.  There are two main groups of ILCs, referred to as natural 
cytotoxicity receptor (NCR) expressing or NCR- subsets.  NCR+ ILC3s express the NK cell 
receptors NKp46 and NKp44, as well as CD11724, 25.  ILC3s have been implicated in a wide 
variety of roles in disease progression.  They interact with the microbiome and have been 
implicated in the control of various bacterial and fungal infections, as well as the formation of 
various secondary lymphoid tissues16.  As with ILC2s, ILC3s are important in driving the 
inflammatory response due to their early production of IL-17 in response to proinflammatory 
signaling by monocytes and other innate cells.  The interaction between various ILC and helper 
T cell derived cytokines is important in the regulation of overall immune response. 
1.2.4 ILCs in the Respiratory Tract 
To date, there are no studies that we know of examining ILC responses in the lung of macaques 
or any other non-human primate model.  ILCs have, however, been studied in a variety of human 
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lung diseases, including chronic obstructive pulmonary disease24, pulmonary fibrosis26, lung 
cancer27, helminth infection14, asthma28 and allergic airway inflammation29.  In these studies, 
ILC populations have been found which correspond to populations previously identified in mice, 
and express the same phenotype and cytokine profiles as ILCs identified in the sinuses, gut, 
lymph node and other secondary mucosal tissues such as gut-associated lymphoid tissue and 
splenic fat-associated lymphoid clusters14, 21.  ILCs have been studied in the gut of rhesus 
macaques in relation to SIV infection25, 30, but these studies have been restricted to examining 
IL-17 producing ILC3s.  However, based on these similarities, we expect that comparably 
analogous populations exist in macaque lung mucosa.   
ILC2s are the primary type of ILC that has been studied in the lung.  The cytokines they 
produce, as well as the cellular product amphiregulin, have been shown to promote mucus 
production and tissue repair in lung14, and the ILC2 product IL-13 has been shown to promote 
epithelial proliferation21.  In influenza infection, these functions have been shown to be critical to 
maintaining the integrity of the alveolar epithelial barrier22, and in fatal infection with H5N1, 
breakdown of this barrier integrity is a driving factor in progression of disease.  In mouse 
models, ILC2s were shown to accumulate in the lung in response to H1N1 influenza infection, 
and provided a protective effect22.  ILC2s have also been shown to enhance and regulate T cell 
responses in IL-13 dependent manner in lung14.  ILC3s have also been identified in the human 
respiratory tract24, 27.  There is evidence of interplay between ILC2s and ILC3s which further 
regulates inflammation29.  IL-22 dependent ILC3s promote epithelial cell function and 
suppressing inflammatory response14, 29.  In chronic inflammatory diseases, there has been a 
demonstrated shift in ILC populations away from ILC2s to ILC3s, indicating that ILC3 play a 
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role in mediation of inflammation as well as ILC224, and it has been demonstrated that the 
distribution of ILC populations altered in human lung disease14, 24 
It is important to note, however, that not all ILC responses that have been seen in the lung 
are protective.  There are several instances where detrimental ILC2 response were seen in atopic 
and allergic diseases13, including allergic airway hyperactivity13, 31.  This ILC mediated airway 
hyperreactivity has also been demonstrated in mouse models of influenza after infection with 
H3N1viruses32, and the associated inflammation contributed to influenza pathology.  Therefore, 
while ILCs promote barrier integrity and cell repair in acute respiratory infection, they may also 
play a role in the pathology of cytokine storms and inflammatory damage. 
Overall, ILCs have been shown to be a relatively minor population in the lungs of both 
mice and humans, making up a total of around 0.02-0.08% of all CD45+ cells in a healthy adult 
lung23, but they play an important role in the progression of many diseases.  Identifying these 
cells in a macaque model could prove useful in understanding their role in the control of 
respiratory diseases. 
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2.0  SPECIFIC AIMS 
To elucidate the mechanisms of the host immune response to H5N1 infection, the aims of this 
project are to develop a strategy to identify ILCs and NK cells in cynomolgous macaque tissues 
via flow cytometry.  Specifically, we want to identify whether infection with H5N1 alters the 
populations of these cells in the respiratory tract. 
In order to understand the dynamics that NK cells and ILCs play in H5N1 infection, we 
plan on first characterizing the cells in lung tissue, and quantifying them in order to compare 
between infected macaques and uninfected control animals.  Previous data generated by our lab 
suggests that there is a depletion of NK cells in the peripheral blood of infected animals.  We 
hypothesize that there will be a similar viral-mediated depletion of NK cells in the respiratory 
tract.  Based on previous studies, there are indications that ILCs will be increased in the site of 
infection, so we hypothesize that we will be able to identify a population of lung-resident ILCs 
that proliferating.  Because both NK cells and ILCs have been indicated in mediating protective 
immune responses against influenza, characterizing them in relation to severe disease will be 
helpful in understanding the immune responses to H5N1 infection, and if there are any potential 
links between these innate immune cells and correlates of protection against severe disease or 
mortality.  This information can be used to help aid the treatment of severe influenza infections 
or develop novel therapeutic strategies. 
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3.0  METHODS 
3.1 VIRAL INOCULATION AND GENERATION OF ANIMAL SAMPLES 
Samples for my work were previously generated during a study of macaques infected with H5N1 
virus as described previously by Wonderlich et al.33  Briefly, seven healthy adult female 
cynomolgus macaques were inoculated via the aerosol route with highly pathogenic avian 
influenza A/Vietnam/1203/2004 (H5N1) virus.  Virus was provided by Dr. Daniel Perez at the 
Department of Population Health, University of Georgia.  Macaques were exposed to small-
particle aerosols of virus for a mean duration of 24.3 minutes, and dose was calculated based on 
each individual macaque’s respiratory volume and nebulizer viral concentration.  The mean dose 
of inoculation was 6.72log10 PFU (Table 1).  Macaques all either succumbed to respiratory 
failure or were humanely sacrificed due to symptom progression by six days post-infection, with 
a mean time-to-death of 3.2 days. For this analysis, cryopreserved single cell suspensions of 
various tissues were thawed and stained for flow cytometric analysis.  Tissue samples were 
prepared by Elizabeth Wonderlich and Simon Barratt-Boyes as described33. All work was carried 
out in the University of Pittsburgh’s Regional Biocontainment Laboratory biosafety level 3 
facility.  
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Table 1. Characteristics of Animals’ Aerosol Exposure 
Animal ID Viral Titer (log10 PFU) Time to death (days) 
132 7.26 3 
133 7.17 2* 
134 7.07 6* 
135 6.16 3 
136 6.46 2* 
137 6.37 2* 
138 6.57 4 
Mean 6.72 3.2 
*- animal humanely sacrificed 
3.2 FLOW CYTOMETRY 
Classical NK cells have been relatively well studied, and NK cell activation panels in macaques 
have previously been established34.    The definition of NK cells used in this study was CD45+ 
lymphocytes, lacking expression of lineage markers for T cells, B cells and monocytes.  In 
macaques, NK cells also express CD8α.   They can further be divided into subsets that express 
either CD16 or CD56.  There are several NK cell specific surface markers that can be used as 
additional positive inclusion gating, but for this panel we chose to use NKG2A, which has been 
shown to be widely expressed on macaque NK cells. 
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 ILC subsets were more difficult to define via extracellular surface markers alone, since 
they are less well-studied, and there is not a universally agreed-upon definition of pan-ILC 
markers.  Therefore, development of the ILC panel is described in detail below. 
3.2.1 ILC Surface Marker Identification 
Since universal nomenclature based on surface markers have not been established, the first step 
we undertook was to establish a literature review to decide how to define and identify ILCs in 
tissues.  Because we had previously determined that in this study, we were primarily interested in 
the behavior of classical NK cells, and there was very little information that suggested non-lytic 
ILC1 would be of particular import in acute respiratory infection, we decided to look exclusively 
at Type 2 and 3 ILCs.  Different studies have identified different gating strategies for various 
tissues, species, and disease states, so we needed to synthesize the results of previous studies to 
create a profile of surface markers that we would identify as ILCs.  Table 2 summarizes the 
distribution of surface markers that have been used to identify Type 2 and 3 ILCs in previous 
studies, and which tissue/species they have been identified in. 
 17 
Table 2. ILC Surface Markers 
 Surface 
Marker 
ILC2 in Human 
22-24 
ILC3 in Rhesus 
Macaque25 
CD16 - - 
CD25 + - 
CD56 - - 
CD90 + + 
CD117 +/- + 
CD127 + + 
CD161 + - 
CRTH2 + - 
NKp30 - + 
NKp44 - + 
T1-ST2 + - 
 
  
 
It is believed that in humans, all ILC subtypes require IL-7 to drive their development, and 
therefore express CD127, which is the IL-7 receptor subunit α.  Additionally, another surface 
marker which has been demonstrated on all ILC subtypes is CD90, which is a costimulatory 
molecule for activation and proliferation signaling.  It has been shown that anti-CD90 antibodies 
leads to pan-ILC depletion22, however, while ILCs express CD90 at increased levels, it is not 
ubiquitously expressed by all cells.  Another point of interest to note is that while CD117 has 
been indicated as a ILC3-specific surface marker in both macaques and humans24, 30, other 
studies suggest that some fraction of CRTH2 expressing ILCs also express CD117.  Whether this 
holds true in the respiratory tract of nonhuman primates is unknown.   
3.2.2 Panel Development 
Having decided on the definition to use for both ILCs and NK cells, two full flow cytometry 
panels were developed.  While I had hoped to be able to identify both NK cells and ILCs out of a 
single panel to identify both subsets of ILCs at the same time, to better facilitate quantitative 
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analysis of changes in populations, ultimately due to constraints in available fluorochrome 
conjugations, the panels were separated into one identifying NK cells, and one identifying ILCs, 
keeping lineage markers consistent between the two.   
Table 3. Flow Cytometry Panels for NK Cell and ILC Identification 
Laser BP Filter Fluorochrome NK Cells ILC 
UV 
335nm 450/50 DAPI Live/Dead  Live/Dead 
Violet 
405nm 
450/50 Pac Blue CD3/CD20 CD3/CD20 
525/50 V500 
 
 CD90 
Blue 
488nm 
530/30 FITC CD45 CD45 
575/26 PE CD56 CD127 
710/50 PerCP- Cy5.5 CD163 CD163 
780/60 PE-Cy7 CD8   
Red 
633nm 
660/20 APC NKG2A CRTH2 
780/60 APC-Cy7 CD16 CD117 
 
3.2.3 Staining and Analysis 
Cryopreserved single-cell tissue suspensions were stained with extracellular labeling antibodies.  
Prior to staining, all cells were counted using trypan blue exclusion assay, and 1 X 106 live cells 
per test were stained with antibodies for 35-45 minutes as per protocol.  Non-viable cells were 
excluded by staining with Live/Dead Fixable UV stain kit from ThermoFisher.  Single or 
multiple antibody leave-outs were used as fluorescence-minus-one controls to determine 
negative gating.  All samples were run on BD LSRII cytometer using BD FACSDiva software, 
and analyzed using FlowJo software version 10.x.  Statistical analysis was performed using All 
analyses were performed using GraphPad Prism v7.  A p value of <0.05 was considered 
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significant, using two-tailed nonparametric Mann-Whitney test, comparing means between naïve 
control and infected animal samples. 
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4.0  RESULTS 
4.1 IDENTIFICATION OF ILC SUBSETS 
4.1.1 ILCs reside in hilar lymph node and lung tissue of cynomolgous macaques 
The ILC panel was run in two tissues of interest to see if there were ILCs which could be 
identified using the ILC panel in different tissue.  I looked at hilar lymph node, and lung tissue to 
try and identify both type 2 and type 3 ILCs. ILCs were defined as CD45+ lymphocytes lacking 
expression of lineage markers identifying T cells, B cells and monocytes using CD3, CD20 and 
either CD163 or CD14, respectively.  CD163 was used in lung tissue while CD14 was used as a 
monocyte marker in lymph node.  These populations then were examined for their differential 
expression of CD127, CD117 and CRTH2. 
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Figure 2. ILC2 and ILC3 Populations in Naive Hilar Lymph Node and Naive Lung Tissue 
Populations highlighted in red are ILC2 and ILC3 subtypes expressing characteristic markers. 
Both hilar lymph node and lung tissues had distinct populations of CD127/CD117 double 
positive ILC3s.  While ILC3s have been previously demonstrated to be resident in various 
mucosal tissues, mesenteric and peripheral lymph nodes as well as PBMCs in macaques prior to 
this study, they have not been shown to be resident in lung tissue before.  In hilar lymph node as 
well as lung there is a very limited population that expresses the characteristic ILC2 marker 
CRTH2.  However, it is assumed that CRTH2+ cells that are potentially ILC2s. 
Naïve hLN 
Naïve Lung 
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4.2 COMPARISON OF ILC SUBSETS BETWEEN INFECTED AN NAÏVE 
ANIMAL SAMPLES 
4.2.1 Changes in distribution of lymphocyte populations 
There were several overarching themes that were seen when examining the differences between 
infected lung tissue compared to healthy controls.  The proportion of live cells that were CD45+ 
lymphocytes was higher in infected animals (Figure 2).  The remaining live cell population that 
did not express CD45 was presumably largely composed of epithelial cells. This corroborates 
results seen in our previous work33 that virus-mediated epithelial cell death contributes to the 
breakdown of the alveolar barrier integrity.  Another important change seen in infected lungs 
was that the proportion of T cells decreased, while the proportion of cells that were negative for 
all lineage markers (a population which includes both NK cells and ILCs) more than doubled in 
comparison to control animals.  This is in respect to the entire proportion of live cells in the 
sample, not just CD45+ lymphocytes.  These changes could be indicative of an overall 
infiltration of lymphocytes into the lung, in conjunction with epithelial cell death.  Also of note is 
a relative increase in monocytes and a decrease in the population of T and B cells.   
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Figure 3. Change in Cell Populations in Lung Tissue 
A) Representative images of gating for CD45 and lineage markers in naïve vs infected lung tissue. B) The percent of 
total live cells in each sample that are CD45+ lymphocytes as opposed to CD45- epithelial cells are significantly 
increased in the lung tissue of infected macaques.  The percent of all live cells that lack lineage markers for T cells, 
B cells and macrophages are also significantly increased in the infected lung. 
4.2.2 NK cells decrease in infected animals 
NK cells were identified in lung suspensions of infected compared to naïve control animals.  NK 
cells were defined as CD45+Lineage-CD8+ cells that were either CD16+ or CD56+. In the lungs 
of cynomolgous macaques, the NK cell population that was found was overwhelmingly CD16+, 
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with hardly any expression of CD56+ NK cells seen (Figure 4).  While CD56 is considered an 
NK-specific cell marker in humans, in macaques CD56+ NK cells are a relatively minor 
population34, however, there are typically a small percentage (<5%) that can be found in 
lymphoid or other tissues that we did not observe in lung tissue.   
Overall, the proportion of Lineage- cells that were identified as CD16+ NK cells were 
significantly decreased (p=0.036) in infected animals compared to control animals.  This is 
consistent with previous studies in vitro which suggest influenza evades NK cell activity by 
directly infecting them and inducing cell death.  Furthermore, the inhibitory molecule NKG2A 
had significantly decreased expression on the population of CD16+ NK cells that were found in 
infected animals compared to uninfected controls.  NKG2A is typically expressed ubiquitously 
on macaque NK cells, so this is clearly a departure from normal cellular function, but whether 
this represents increased activation of NK cells or a functional perturbation is unclear. 
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Figure 4. NK Cells Decrease in the Lungs of Infected Animals 
A) Representative gating of naïve control animals compared to H5N1 infected lung tissue staining for NK cells.  NK 
cells are defined as CD45+ Lineage-CD8+ cells that are either single or double positive for CD16 or CD56.  Nearly 
all CD45+ Lineage-CD8+ cells in the lung are CD16 single positive NK cells in both infected and uninfected 
animals.  B) The population of 16+ NK cells is significantly decreased in infected macaques as a proportion of all 
Lineage- cells.  Of the remaining CD16+ NK cells in the lung, significantly fewer express the surface receptor 
NKG2A. C) Top: Representative gating of increase in NKG2A expression on naïve vs H5N1 infected lung NK cells 
Bottom:  Double leave out negative fluorescence control.
C
Control 
NK cells 
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4.2.3 Changes in ILC distribution during infection 
ILCs were defined in this study as being CD45+, Lineage negative cells (CD3, CD20, and 
CD163) that expressed CD127 (IL-7Rα).  We further explored the expression of CRTH2 and 
CD117, which are specific markers for Types 2 and 3 ILCs, respectively, as well as the 
expression of CD90, which is a surface receptor that provides costimulation for proliferation and 
activation of lymphocytes.  Representative gating for various ILC populations is shown in figure 
5. 
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Figure 5. ILC Expression in Infected Compared to Control Lung Tissue 
A) Representative gating of CD45+ Lineage- lymphocytes.  Top: Populations highlighted in red represent 
CD117/CD127 double positive ILC3s, and CRTH2+ cells in panels 3 and 4, respectively.  Bottom: Double leave out 
negative fluorescence control  B) The mean percentage of lineage negative cells expressing CRTH2+ between naïve 
and infected animals increases non-significantly.  Also shown is the mean percentages of CD117/CD127 double 
positive ILC3s, which had no significant change. 
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ILC expression was highly variable even among control animals.  Type 3 ILCs were 
defined as CD127/117 double positive populations, but there was no statistically significant 
difference between control and infected animal lung.  Likewise, there was no population seen 
that was positive for both CD127 and CRTH2, which would be identified as ILC2.   
However, there was a large CRTH2 positive population seen that did not express CD127, 
and this population did show a trend to increase in infected lungs, but this was not significant 
between naïve and infected animals (p=0.14).    While it has been demonstrated that all ILC 
types express CD127 in human and mouse lung populations, to our knowledge ILC2s have not 
been extensively studied in a macaque model, and further characterization of the functional 
capabilities of this CRTH2+ cell population could elucidate whether they are or are not truly 
ILC2s.  A percentage of this single-positive population also expressed the costimulatory surface 
receptor CD90 (with a mean of 46% of cells, range 3%-90%) (data not shown).  CD90 
expression is commonly seen on ILC populations, and has been used to define ILC subsets, 
although there can be varying degrees of expression22.   
The fact that a portion of the CRTH2+ population expresses CD90 could indicate that 
they are ILCs, but further analysis of function, proving expression of the characteristic 
transcription factor GATA-3 or IL-13 would indicate that they share additional aspects of the 
ILC2 phenotype.  CRTH2 can be expressed by other cell types, including T cells, however, it is 
unlikely that this population includes T cells due to the lack of CD3 expression.  Another 
observation when classifying these subsets of ILCs is that a significant proportion of CRTH2+ 
cells also expressed CD117.  While it has been shown in human respiratory tract ILCs that 
CRTH2 and CD117 define mutually exclusive populations of ILCs24  
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In all, ILCs represented less than 5% of all live cells in the lung in all animals.  The mean 
percentage of CRTH2+ of all live cells in naïve animals was 0.57%, and a mean of 6.15% of all 
live cells in infected animals.  CD117/CD127 double positive ILC3s represented an average of 
1.4% of all live cells in naïve animals and 1.8% of in infected animals.  Despite the apparent 
infiltration of CRTH2+ cells in infected animals, there were no significant changes in ILC 
populations between infected and uninfected animals.   
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5.0  DISCUSSION AND CONCLUSIONS 
As hypothesized, the depletion seen in NK cell populations are consistent with influenza virus 
infection studies performed in vitro18, 20.  The depletion of NK cells in the lung during severe 
respiratory disease provides insight into the pathology of influenza infection.  Specifically, it is 
unknown what the functional mechanism of NK cells is in H5N1 influenza virus infection in 
humans, and whether they have a significant protective effect as has been demonstrated with 
other viral infections, or whether their depletion is in fact due to virally mediated cell death, and 
is a viral evasion mechanism.  One hypothesis from previous studies is that the depletion of NK 
cells during H5N1 infection could be causally linked to the high pathogenicity and case fatality 
of the disease compared to milder seasonal influenzas19, although much more work is needed in 
this arena to demonstrate this experimentally.  Future work to identify whether NK cells in H5N1 
infected lungs in our animal model are directly infected would provide further evidence that the 
NK cell depletion shown here is in fact mediated by direct viral infection of NK cells, or whether 
there are other additional immune evasion mechanisms at play would be useful in understanding 
the acute response to viral infection. 
The identification of ILCs in macaques is a novel finding that has implications for the 
study of a variety of human diseases.  Additional experimentation is necessary to determine 
whether the populations of cells that I identified as potential CRTH2+ ILC2s express cytokines 
and transcription factors consistent with ILC2s identified in humans and mice.  However, if these 
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ILC2 and ILC3 subsets that were identified prove to have consistent functional profiles in 
addition to these suggestive phenotypes, it would be beneficial to the field of ILC research in 
several ways.  For one, ILC2 have not been extensively studied in a macaque model, and so 
identifying them opens up whole new classifications of diseases in which ILC2s have been 
shown to be important, including respiratory disease but also diseases such as helminth infection 
and atopic allergic diseases, to study in a non-human primate model.  However, the identification 
of this subset raises some additional questions about the phenotype of macaque ILC2s, such as 
why these CRTH2+ cells do not express CD127.  Since CD127 is the receptor for IL-7, and IL-7 
is thought to be required for ILC development12, it was previously used as an identifier for all 
ILC subsets.  If further experimentation bears out the hypothesis that these CRTH2+ cells have 
additional ILC2 characteristics, it would be pertinent to understand why they lack CD127, if this 
is an altered phenotype seen only due to infection, whether there is something fundamentally 
different about the development of ILCs in the macaque immune system, and whether this 
finding changes our approach to studying these cells in non-human primates.  
While additional experimentation is needed to prove that the CRTH2 subsets identified 
phenotypically share other hallmarks of ILC function such as characteristic cytokine production 
or transcription factors, there is a strong trend suggesting that they are increasing during acute 
influenza infection.  Since infiltration of ILC2s into influenza infected lungs was hypothesized, it 
seems plausible that the CRTH2+ expressing subset of lineage negative cells are likely to be 
ILC2s even if they do not express the characteristic surface marker CD127.  Despite the fact that 
these cell types remain minor populations in both healthy and infected lung, they play a critical, 
as of yet under-studied role in shaping the early innate immune response to infection, and are 
worth studying in more depth in models of severe disease.   
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Further work characterizing the function of ILCs in the lung during HPAI H5N1 
influenza infection would also be useful to understand the mechanisms underlying protective 
immunity to influenza.  It is apparent that influenza pathology in severe disease is at least 
partially mediated by the immune response and cytokine storm caused by upregulation of 
inflammatory cytokines.  As such, understanding the innate mechanisms that promote or control 
cytokine production and regulate early inflammation is critical in understanding the mechanisms 
of influenza pathology.  Understanding which mechanisms of immunity lead to protective 
responses compared to those which increase the severity of disease could lead to novel 
treatments.  Since breakdown of epithelial barrier integrity is a hallmark characteristic of ARDS, 
ILC products such as amphiregulin that support tissue repair and epithelial cell proliferation 
could prove to be an important mechanism for protecting against severe disease, and further 
research into these mechanisms could provide new avenues to explore towards therapeutic 
strategies for severe respiratory distress.  If the role of ILCs were better understood in severe 
disease, this could lead to the development of new strategies to combat avian influenza outbreaks 
in humans.   
The development of novel therapeutic strategies is particularly important when discussing 
the public health impact of avian influenza.  Because H5N1 causes rapid onset disease with 
severe morbidity and mortality, treatment options are currently limited.  If a crossover event or 
viral reassortment ever did lead to a strain of H5N1 virus that was easily transmissible between 
humans, there would be an incredible need for additional treatments.  Currently, influenza 
preparedness centers largely around prevention of infection through vaccination35.  While this 
strategy works well at preventing and containing infection, the potential for the sudden 
emergence of new strains for which vaccines are not yet developed (or are developed but we 
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have inadequate quantities to vaccinate large populations at once), leaves major gaps in global 
influenza pandemic preparedness.  While there are several licensed H5 vaccines for poultry, and 
candidate vaccines exist for human use, there are still several drawbacks to this strategy of 
preparedness.  For one, these vaccines are largely untested, and while their immunogenicity and 
efficacy can be tested in small-scale clinical trials, without an outbreak of cases it is impossible 
to completely predict their actual effectiveness at preventing disease or mortality.  Antiviral 
drugs such as oseltamivir are another strategy to prepare against the potential of an influenza 
pandemic35. While modeling suggests that these drugs could be effective at preventing the large-
scale spread of novel influenza viruses, there are also concerns about antiviral resistance and 
questions about the efficacy of antivirals as post-exposure prophylactics36.  As such, the 
development of therapeutics that are particularly effective against avian influenza could be 
beneficial in terms of public health preparedness and pandemic response.  Even more broadly, 
immunotherapeutics against severe respiratory inflammation could be beneficial for a number of 
human diseases, including a variety of acute viral infections that cause ARDS. 
5.1.1 Future aims 
Having a non-human primate model in which to study symptomatic H5N1 avian influenza is an 
incredibly useful tool to understanding the correlates of disease and immunity that cannot be 
studied in humans in the absence of a large outbreak.  Additionally, having identified a potential 
population of cells that resemble human ILCs in the lung, the next step would be to examine 
their cytokine production when stimulated, and see if this also corresponds to human ILC 
populations.  Further work with ILCs in the respiratory tract could lead to better understanding of 
not only the response to acute viral respiratory infections, but to a wide variety of inflammatory 
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and chronic lung diseases in which ILCs may play a vital part.  Likewise, an in vivo NK cell 
model could contribute to more basic research about innate response to influenza viral infection, 
and understanding the mechanism of innate response is a key aspect of being able to control 
acute viral infections.  Being able to study these cells in vivo in nonhuman primates could prove 
an important tool for understanding their role in the immune system. 
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